SAN FRANCISCO — Positive results were found in two pivotal safety and efficacy studies that looked at lurasidone HCl treatment in patients with depressive disorders associated with bipolar I disorder.
In the PREVAIL 1 study, 348 patients with bipolar depression were assigned lurasidone HCl (Latuda, Sunovion Pharmaceuticals; 20 mg/day to 120 mg/day) with or without rapid cycling as adjunctive therapy to lithium or valproate for 6 weeks. Metabolic changes in lipids, glucose, weight and insulin were assessed.
Full Story »
Personalize your page!
Register for Healio to get content tailored to your specialty and areas of interest.
It’s FREE and only takes one minute.